Imagen en el ictus isquémico agudoneurodonostia.com/wp-content/uploads/2017/03/4... · Objetivos...

Post on 26-Jul-2020

3 views 0 download

Transcript of Imagen en el ictus isquémico agudoneurodonostia.com/wp-content/uploads/2017/03/4... · Objetivos...

Imagen en el ictus isquémico agudo

Gorka Arenaza

?

Objetivos de la imagen 1.-Descartar simuladores e ictus hemorrágicos

2.-Oclusión vascular 3.-Core y Penumbra

Emergency imaging before any treatment

Nonenhanced CT will provide necessary information

(Class I; Level of Evidence A)

TAC RM

If endovascular therapy is contemplated, a noninvasive intracranial vascular study is strongly recommended

(Class I; Level of Evidence A)

Patients should receive endovascular therapy with ICA or M1 occlusion

(Class I; Level of Evidence A)

Endovascular therapy may be reasonable M2-M3, ACA and posterior circulation

(Class IIb; Level of Evidence C)

Objetivos de la imagen 1.-Descartar simuladores e ictus hemorrágicos

2.-Oclusión vascular 3.-Core y Penumbra

William T. C. Yuh, AJR 2017 208:1, 32-41

ASPECTS

100-35 35-35

Pat

ien

ts s

ho

uld

re

ceiv

e e

nd

ova

scu

lar

the

rap

y w

ith

ASP

ECTS

≥6

(Cla

ss I;

Lev

el o

f Ev

iden

ce A

)

ASP

ECTS

co

mo

cri

teri

o d

e

incl

usi

ón

MR

CLEA

N

----

ESCA

PE

≥6

EXTE

ND

IA

----

SWIF

T PR

IME

≥6

REVA

SCAT

≥7

Alt

ho

ugh

its

be

nef

its

are

un

cert

ain

, e

nd

ova

scu

lar

the

rap

y m

ay b

e

reas

on

able

) w

ith

in 6

ho

urs

of

sym

pto

m o

nse

t an

d A

SPEC

TS <

6

(C

lass

IIb

; Lev

el o

f Ev

iden

ce B

)

Imágenes fuente

Int J Stroke 2008;3(4):230–6

Colaterales

Bijoy K. Menon et al; Radiology 2015, 275, 510-520.

www.aspectsinstroke.com

Christopher D. d’Esterre et al. International Stroke Conference 2017

The benefits of collateral measurement for selecting patients for endovascular therapy are unknown

(Class IIb; Level of Evidence C)

*Further trials may be helpful to determine if collateral status is beneficial for

ASPECTS <6 or beyond 6 hours

Colaterales como criterio

de inclusión

MR CLEAN ----

ESCAPE mCTA

EXTEND IA ----

SWIFT PRIME ----

REVASCAT ----

TC Perfusión

Christopher D. d’Esterre et al. Stroke. 2015;46:3390-3397

MTT CBVol

Tmax Tmax

Perfusión

MR CLEAN ----

ESCAPE ----

EXTEND IA Ratio 1.2 Core<70

SWIFT PRIME Ratio 1.8 Core<50

REVASCAT CBV>6

The benefits of perfusion for selecting patients for endovascular therapy are unknown

(Class IIb; Level of Evidence C)

Further trials may be helpful to determine if perfusion is

beneficial for ASPECTS <6 or beyond 6 hours

Hospital Ntra. Señora de Aránzazu, 1993 Dr Massó

N.Takakura RSNA 2014

Conclusiones • CT basal y AngioTC obligatorio • Core / Penumbra pendiente de estandariación,

validación • Herramientas prometedoras para aumentar

ventana terapeútica y disminuir recanalización fútil

“Tiempo es cerebro” Penumbra

¡Muchas gracias!

gorka.arenazachoperena@osakidetza.net